NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)
ID: 356683Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356683

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-033.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for the establishment of Network Lead Academic Participating Sites (LAPS) within the National Clinical Trials Network (NCTN) to enhance cancer clinical trials for adult patients. This initiative aims to foster scientific leadership and collaboration among U.S. Network Groups, with a focus on robust trial accrual and outreach to underrepresented populations. The NCI plans to allocate up to $35.1 million to support 32 to 40 awards, with each award having a maximum budget of $1.7 million per year over a six-year project period. Interested applicants can find more information and application guidelines at the provided link, with proposals due by February 24, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-033.html
    The National Cancer Institute (NCI) is issuing a Notice of Funding Opportunity (NOFO) to support the establishment of Network Lead Academic Participating Sites (LAPS) within the National Clinical Trials Network (NCTN) for cancer clinical trials. The aim is to enhance scientific leadership in clinical trial development and execution, specifically for adult cancer patients, while fostering collaboration with U.S. Network Groups. The funding opportunity seeks applications from higher education institutions and associated organizations, offering up to $35.1 million to support 32 to 40 awards, with a maximum budget of $1.7 million per year over a six-year project period. Eligible applicants must demonstrate substantial capabilities in robust trial accrual, including outreach to underrepresented populations. The submission process includes adherence to strict guidelines and utilization of updated application forms. Proposals should showcase past achievements, institutional capabilities, and a clear strategy for patient recruitment and trial activation. The review process will assess project significance, scientific merit, and the ability to address challenges in trial execution. This funding initiative reflects the NCI's commitment to advancing cancer treatment research through collaborative and innovative clinical trials.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network, specifically targeting Network Lead Academic Participating Sites through a cooperative agreement. The primary objective is to provide scientific leadership in developing and conducting multi-center clinical trials for various cancer treatments, contributing to substantial patient accrual across the NCTN. This initiative is crucial for advancing clinical research and improving treatment options for diverse patient populations affected by cancer. The estimated total program funding is $35,100,000, with an award ceiling of $1,700,000 and approximately 35 awards expected. Interested applicants should prepare for the anticipated application due date in late February 2025, following the NOFO publication in Fall 2024.
    Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention Clinical Trials Network (CP-CTNet) to establish sites for early-phase cancer prevention clinical trials. The initiative aims to develop and conduct trials that assess the safety and efficacy of various preventive agents and interventions targeting specific biological processes associated with cancer development, with a focus on recruiting high-risk participants and conducting multi-institutional studies. This funding underscores the importance of advanced research in cancer prevention, with a total funding amount of $8.75 million annually to support five awards over six years, each with a budget not exceeding $1.375 million. Interested applicants must submit a letter of intent by August 23, 2024, and a complete application by September 30, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required). This initiative invites applications primarily from current award recipients under RFA-CA-17-057 to sustain Statistics and Data Management Centers (SDMCs) for the NCI National Clinical Trials Network (NCTN), which focuses on advancing cancer treatment through multi-center clinical trials, particularly late-phase trials and biomarker-driven therapies. The funding, totaling approximately $47 million, aims to support five awards over a project period of up to six years, emphasizing the need for substantial Federal scientific involvement and robust statistical analysis plans. Interested applicants must submit their proposals by January 24, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for a single-source grant aimed at establishing the NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network. This initiative seeks to partner with private institutions of higher education to conduct large-scale, multi-site clinical trials, focusing on late-phase treatment trials and advanced imaging across various cancer types, while ensuring regulatory oversight in Canada. The funding, estimated at $3.8 million, is intended to support the NCTN's efforts to enhance clinical research for diverse patient populations, with the application due in late February 2025 and the award anticipated by March 1, 2026. Interested applicants should prepare their proposals in advance of the expected NOFO publication in Fall 2024.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Cancer Prevention Clinical Trials Network (CP-CTNet) to establish a Data Management, Auditing, and Statistical Center (DMASC) through a cooperative agreement. This initiative aims to support the design and execution of early-phase clinical trials focused on cancer prevention strategies, assessing the safety, tolerability, and efficacy of various interventions while enhancing operational efficiencies and data integration across the network. The DMASC will play a crucial role in providing centralized data management, auditing clinical trial processes, and offering statistical support, ultimately addressing significant public health challenges related to cancer prevention. The project is set for a six-year period with an annual funding commitment of $3,250,000, and interested applicants must submit their proposals by October 31, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)" aimed at fostering collaborations between institutions serving underserved populations and NCI-designated Cancer Centers. The initiative seeks to enhance cancer research capacity, promote workforce diversity, and implement community outreach initiatives to address cancer health disparities. This program is vital for developing comprehensive research projects that include administrative cores, research education, and outreach efforts, ultimately contributing to a stronger national cancer program. Eligible applicants can request funding of up to $2.2 million over five years, with the application submission period starting on December 15, 2023. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required). This initiative aims to provide statistical expertise for the design, conduct, and data management of multi-center clinical trials, particularly focusing on late-phase treatment trials across various cancer types and patient demographics. The funding, estimated at $47 million, will support approximately five awards, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, interested applicants should prepare their proposals in advance of the anticipated timeline.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.